Biologic therapies for psoriasis: Practical experience in a U.K. tertiary referral centre

British Journal of Dermatology

Volumn 160, Issue 1, 2009, Pages 162-169

  Warren, R B ^a   Brown, B C ^a   Lavery, D ^a   Ashcroft, D M ^a   Griffiths, C E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biologic therapy; Efalizumab; Etanercept; Infliximab; Psoriasis

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ANTINUCLEAR ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BALANCE DISORDER; BIOLOGICAL THERAPY; CELLULITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORNEA ULCER; CROHN DISEASE; DEPRESSION; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPLASTIC NEVUS; EOSINOPHILIA; ERYTHEMA; EXTERNAL OTITIS; EYE DISEASE; EYELID EDEMA; FEMALE; FLU LIKE SYNDROME; FLUSHING; FURUNCULOSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEMATURIA; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; IRRITANT DERMATITIS; LETHARGY; LIVER FUNCTION TEST; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYALGIA; NATIONAL HEALTH ORGANIZATION; NAUSEA; PAPILLOMA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; RELAPSE; RHINOSINUSITIS; SCLERITIS; SEBACEOUS CYST; SEPTICEMIA; SIDE EFFECT; SKIN CANCER; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; TERTIARY HEALTH CARE; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERRUCA PLANTARIS; VIRUS INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57649170604     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08865.x     Document Type: Article

References (23)

1. National Institute for Health and Clinical Excellence. Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. 2006. Available at: http://www.nice.org.UK/TA103 (last accessed 25 July 2008).
2. National Institute for Health and Clinical Excellence. Infliximab for the Treatment of Psoriasis. 2008. Available at: http://www.nice.org.UK/TA134 (last accessed 25 July 2008).
3. National Institute for Health and Clinical Excellence. Adalimumab for the Treatment of Psoriasis. 2008. Available at: http://www.nice.org.UK/TA146 (last accessed 30 August 2008).
4. ®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 155 : 170 81.
5. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 290 : 3073 80.
6. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 22.
7. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 12.
8. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 42.
9. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
10. Ormerod LP. Tuberculosis and anti-TNF-alpha treatment. Thorax 2004 59 : 921.
11. Fredriksson T. Oral treatment of psoriasis and pustulosis palmo-plantaris with Ro 10-9359. Dermatologica 1978 157 (Suppl. 1 13 18.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
13. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 97.
14. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008 58 : 443 6.
15. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 2007 156 (Suppl. 2 1 6.
16. Antoniou C, Stefanaki I, Stratigos A et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol 2007 156 (Suppl. 2 12 16.
17. Costanzo A, Peris K, Talamonti M et al. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007 156 (Suppl. 2 17 23.
18. Ferrandiz C, Carrascosa JM. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. Br J Dermatol 2007 156 (Suppl. 2 24 9.
19. Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007 156 : 1010 14.
20. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 2005 32 : 752 3.
21. Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br J Dermatol 2007 157 : 396 (Letter).
22. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 : 711 16.
23. Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003 139 : 752 6.